Pharmaceuticals

Adalimumab, Infliximab and Etanercept Biosimilars Industry Overview 2025: Growth Projections and Market Trends

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Adalimumab, Infliximab and Etanercept Biosimilars Market Covering 2025–2034?

The adalimumab, infliximab and etanercept biosimilars market has experienced rapid expansion in recent years. It is projected to grow from $4.37 billion in 2024 to $4.96 billion in 2025, at a compound annual growth rate (CAGR) of 13.6%. This historical growth can be attributed to increased healthcare expenditure, evolving regulatory landscapes, government initiatives, and rising healthcare costs.

The adalimumab, infliximab, and etanercept biosimilars market size is poised for significant expansion over the next few years. It is projected to increase to $7.34 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.3%. This growth during the forecast period is primarily attributable to rising healthcare expenditure, a demographic shift towards an aging population, and enhanced access to healthcare. Prominent trends anticipated in the forecast period encompass an emphasis on introducing new products, pursuing mergers and acquisitions, forging strategic partnerships, and boosting investment.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Which Factors And Drivers Are Influencing The Adalimumab, Infliximab and Etanercept Biosimilars Market In 2025?

The cessation of patent protection for branded drugs enables biosimilars to enter the adalimumab, infliximab, and etanercept biosimilars market. For instance, in the United States, the FDA granted approval to Inflectra, developed by Hospira (a Pfizer Inc. company), for treating various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, subsequent to the patent expiry of the branded drug Remicade. In a similar vein, Amgen’s Enbrel had its patent expire in the EU, and this expiration facilitated the European Commission’s approval of Benepali, a biosimilar of Enbrel. Furthermore, Humira’s patent lapsed, making its biosimilars available in the market, with the FDA recently approving Hulio, the sixth biosimilar of Humira. These instances collectively indicate that the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade will thus propel the demand within the adalimumab, infliximab, and etanercept biosimilars market.

What Are The Major Segments Identified In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Which Trends Are Impacting The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies active in the adalimumab, infliximab, and etanercept biosimilars market are concentrating on developing innovative offerings, such as citrate-free adalimumab, to deliver reliable services to customers. Citrate-free adalimumab represents a version of the biological drug adalimumab that is formulated without citrate. For example, in December 2022, Fresenius Kabi, a Germany-based producer of pharmaceuticals and equipment for infusion, transfusion, and clinical nutrition, declared that its biosimilar Idacio (adalimumab) had received FDA approval for managing chronic autoimmune disorders across all authorized applications of the reference product. This product was developed utilizing advanced analytical techniques for its use in treating numerous chronic health issues.

Which Major Industry Participants Are Leading The Adalimumab, Infliximab and Etanercept Biosimilars Market Growth?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

What Are The Regional Market Dynamics Impacting The Adalimumab, Infliximab and Etanercept Biosimilars Industry?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Adalimumab, Infliximab and Etanercept Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2025, By The Business Research Company

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2025

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Trastuzumab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795